Phase 3 trial of leniolisib in activated PI3Kδ syndrome, dabrafenib plus trametinib in relapsed/refractory hairy cell leukemia, and TγδLGL leukemia as a more symptomatic subset of leukemia
Blood Podcast
00:00
Relapsed Refractory BRAF V600E Mutation Positive HCL
The MRD negativity rate, per protocol definition of negative immunohistochemistry of bone marrow biopsy, was 9.1%. Pyrexia, chills, and hyperglycemia were the most common treatment-related adverse events. The authors concluded that Dabrafenib, in combination with Trometinib, demonstrated durable responses with an acceptable safety profile.
Transcript
Play full episode
